Omalizumab a new prospective: a nasal polyposis

C. Cavaliere; E. Begvarfaj; F. Frati; S. Masieri

doi:10.54517/jbrha5042

Publication Frequency

Quarterly since 2025

Journal Articles

Search scope

Journal Center

Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

more

Volume Arrangement

2025

Vol 39, No 3 (2025)

Vol 39, No 2 (2025)

Vol 39, No 1 (2025)

Featured Articles

Macrophages in the pathogenesis of psoriasis and anti-psoriatic nanotherapies

Psoriasis is a common, chronic, and inflammatory skin disease. Macrophages account for about 61.3% of the inflammatory cells infiltrating psoriatic lesions. Modulating macrophage polarization, inhibiting their infiltration, and targeting the secretion of inflammatory factors and associated inflammatory pathways by these cells can alleviate psoriasis symptoms and inflammation. Moreover, nanomaterials as novel drug carriers, offer unique advantages such as large surface area, easy modification, high biocompatibility, good biodegradability, enhanced systemic adsorption, etc. Nanomaterials have great potential for efficient drug delivery and release, as well as improving therapeutic efficacy while reducing adverse effects. By systematically addressing the role of macrophages in psoriasis pathogenesis and the potential of nanomaterials in treating psoriasis through modulating macrophages, this review enhances our understanding of the disease mechanism and holds promise for novel therapeutic breakthroughs and advancements in the future treatment of psoriasis.

Omalizumab a new prospective: a nasal polyposis

C. Cavaliere, E. Begvarfaj, F. Frati, S. Masieri

Article ID: 5042
Vol 32, Issue 1, 2018

DOI: https://doi.org/10.54517/jbrha5042

Received: 11 March 2018; Accepted: 11 March 2018; Available online: 11 March 2018; Issue release: 11 March 2018

Abstract

Omalizumab, a monoclonal antibody against IgE, may be effective on nasal polyps, but its use is not currently authorized to treat that disease. We report the cases of three patients who were given omalizumab for asthma after undergoing nasal surgical polypectomy. Although such procedure is frequently followed by polyp recurrence, none of the three patients developed this complication, and in one subject the regression of initial polyp return was registered after starting omalizumab. Our data support the hypothesis that omalizumab may be useful to treat nasal polyposis

Keywords

Omalizumab;nasal polyposis;chronic rhinosinusitis

References

Supporting Agencies

This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Editor-in-Chief

Dr. Fabio Malavasi

Medical Genetics, University of Torino Medical School, Italy

Co-Editor-in-Chief

Prof. Marcello Iriti

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy

Indexing & Archiving

News & Announcements

2025-02-01

Notice of Change in Publication Schedule

In addition to the first issue that has already been published by the original publisher, there will be four more issues released this year, with scheduled publication dates in March, June, September, and December respectively.

2025-01-21

Notice: Ownership Transfer of the Journal

Starting from Volume 39 Issue 2 (2025), the ownership of Journal of Biological Regulators and Homeostatic Agents (ISSN: 0393-974X (P); 1724-6083 (O)) will be transferred from Biolife Sas to Asia Pacific Academy of Science Pte. Ltd. As of 21 January 2025, authors should make submissions to the new journal system and follow the author guidelines. Asia Pacific Academy of Science Pte. Ltd. will take over the publication of manuscripts being processed.

More Announcements...